KR102942707B1 - Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법 - Google Patents

Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법

Info

Publication number
KR102942707B1
KR102942707B1 KR1020247036942A KR20247036942A KR102942707B1 KR 102942707 B1 KR102942707 B1 KR 102942707B1 KR 1020247036942 A KR1020247036942 A KR 1020247036942A KR 20247036942 A KR20247036942 A KR 20247036942A KR 102942707 B1 KR102942707 B1 KR 102942707B1
Authority
KR
South Korea
Prior art keywords
base
modified
lpa rnai
sequence
mod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247036942A
Other languages
English (en)
Korean (ko)
Other versions
KR20240162596A (ko
Inventor
스테이시 멜퀴스트
스티븐 캐너
데이비드 비. 로제마
데이비드 엘. 루이스
로렌 제이. 알메이다
대런 에이취 웨이크필드
블라디미르 에스. 트루베트스코이
타오 페이
젠 리
아론 알메이다
Original Assignee
애로우헤드 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애로우헤드 파마슈티컬스 인코포레이티드 filed Critical 애로우헤드 파마슈티컬스 인코포레이티드
Priority to KR1020267008441A priority Critical patent/KR20260046241A/ko
Publication of KR20240162596A publication Critical patent/KR20240162596A/ko
Application granted granted Critical
Publication of KR102942707B1 publication Critical patent/KR102942707B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247036942A 2015-10-01 2016-09-30 Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법 Active KR102942707B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020267008441A KR20260046241A (ko) 2015-10-01 2016-09-30 Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US62/235,816 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US62/346,304 2016-06-06
US201662383221P 2016-09-02 2016-09-02
US62/383,221 2016-09-02
PCT/US2016/054729 WO2017059223A2 (en) 2015-10-01 2016-09-30 Compositions and methods for inhibiting gene expression of lpa
KR1020187010095A KR102728481B1 (ko) 2015-10-01 2016-09-30 Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187010095A Division KR102728481B1 (ko) 2015-10-01 2016-09-30 Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267008441A Division KR20260046241A (ko) 2015-10-01 2016-09-30 Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20240162596A KR20240162596A (ko) 2024-11-15
KR102942707B1 true KR102942707B1 (ko) 2026-03-23

Family

ID=58424351

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247036942A Active KR102942707B1 (ko) 2015-10-01 2016-09-30 Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법
KR1020187010095A Active KR102728481B1 (ko) 2015-10-01 2016-09-30 Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법
KR1020267008441A Pending KR20260046241A (ko) 2015-10-01 2016-09-30 Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187010095A Active KR102728481B1 (ko) 2015-10-01 2016-09-30 Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법
KR1020267008441A Pending KR20260046241A (ko) 2015-10-01 2016-09-30 Lpa의 유전자 발현을 저해하기 위한 조성물 및 방법

Country Status (35)

Country Link
US (4) US9932586B2 (enExample)
EP (2) EP3356529B1 (enExample)
JP (5) JP6991966B2 (enExample)
KR (3) KR102942707B1 (enExample)
AU (3) AU2016331084B2 (enExample)
CA (2) CA3000397A1 (enExample)
CL (1) CL2018000803A1 (enExample)
CO (1) CO2018003678A2 (enExample)
CR (1) CR20180231A (enExample)
CY (1) CY1125263T1 (enExample)
DK (1) DK3356529T3 (enExample)
EA (1) EA038478B1 (enExample)
ES (1) ES2896298T3 (enExample)
HR (1) HRP20211410T1 (enExample)
HU (1) HUE055942T2 (enExample)
IL (3) IL258333B (enExample)
JO (2) JOP20160211B1 (enExample)
LT (1) LT3356529T (enExample)
MA (1) MA43347B1 (enExample)
MX (2) MX2018003833A (enExample)
MY (1) MY195796A (enExample)
PE (1) PE20181139A1 (enExample)
PH (1) PH12018500713A1 (enExample)
PL (1) PL3356529T3 (enExample)
PT (1) PT3356529T (enExample)
RS (1) RS62523B1 (enExample)
SG (1) SG10202008530TA (enExample)
SI (1) SI3356529T1 (enExample)
SM (1) SMT202100622T1 (enExample)
TN (1) TN2018000094A1 (enExample)
TW (4) TWI784934B (enExample)
UA (1) UA121998C2 (enExample)
UY (1) UY36926A (enExample)
WO (1) WO2017059223A2 (enExample)
ZA (1) ZA202106265B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
JOP20170057B1 (ar) * 2016-03-07 2022-03-14 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة كمركبات علاجية
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
US11015198B2 (en) * 2017-04-05 2021-05-25 Silence Therapeutics Gmbh Products and compositions
TN2019000308A1 (en) * 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
SG11201912178VA (en) * 2017-09-11 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
MX2020001912A (es) * 2017-09-14 2020-03-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
SG11202003126VA (en) 2017-10-04 2020-05-28 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and uses thereof
CN111212909A (zh) * 2017-10-17 2020-05-29 箭头药业股份有限公司 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
CN119120476A (zh) * 2017-11-13 2024-12-13 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
US12534728B2 (en) * 2018-09-19 2026-01-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use
AU2019380628B2 (en) * 2018-11-13 2024-10-31 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of LPA in a cell
WO2020247782A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
EP3983077A4 (en) * 2019-06-17 2023-12-20 Alnylam Pharmaceuticals, Inc. DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM
CN112442499B (zh) * 2019-08-30 2026-03-10 恩康药业科技（广州）有限公司 一种抑制MCM7的siRNA、组合物及其应用
JP7827623B2 (ja) * 2019-12-09 2026-03-10 アムジエン・インコーポレーテツド ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法
EP4126967A1 (en) * 2020-03-23 2023-02-08 Amgen Inc. Monoclonal antibodies to chemically-modified nucleic acids and uses thereof
KR20220158011A (ko) * 2020-03-26 2022-11-29 애로우헤드 파마슈티컬스 인코포레이티드 PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법
KR20250077604A (ko) * 2020-08-05 2025-05-30 다이서나 파마수이티컬, 인크. Lpa 발현을 저해하기 위한 조성물 및 방법
EP4229201A1 (en) * 2020-10-16 2023-08-23 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
KR20230104200A (ko) * 2020-11-05 2023-07-07 암젠 인크 LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
US20250034561A1 (en) * 2021-02-18 2025-01-30 Oneglobe Holdings Limited Novel Compositions for Conjugating Oligonucleotides and Carbohydrates
CN117836307A (zh) 2021-06-18 2024-04-05 弘景生物科技有限公司 功能化的n-乙酰基半乳糖胺核苷
EP4396193A4 (en) 2021-08-30 2025-07-02 Hongene Biotech Corp FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES
US20250283076A1 (en) 2021-09-14 2025-09-11 Argonaute RNA Limited Treatment of cardiovascular disease
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
EP4450624A4 (en) * 2021-12-16 2025-03-26 Tuojie Biotech (Shanghai) Co., Ltd. LPA-TARGETTING SIRNA AND CONJUGATE
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
KR20250131826A (ko) * 2023-01-13 2025-09-03 일라이 릴리 앤드 캄파니 치료 올리고뉴클레오티드-함유 제약 조성물 및 그를 사용한 투여 요법
AU2024279456A1 (en) * 2023-05-31 2025-12-04 Arrowhead Pharmaceuticals, Inc. HEPATIC DELIVERY PLATFORMS FOR MULTIMERIC RNAi AGENT CONJUGATES AND METHODS OF USE THEREOF
KR20260020955A (ko) 2023-05-31 2026-02-12 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 LPA를 표적화하는 dsRNA 및 이의 응용
DE102023115075A1 (de) * 2023-06-07 2024-12-12 B.Braun Avitum Ag Schlauchrollenpumpe
UY40897A (es) 2023-09-21 2025-03-31 Ionis Pharmaceuticals Inc Compuestos y métodos para inhibir lpa
TW202540420A (zh) 2023-11-15 2025-10-16 大陸商北京加科瑞康醫藥科技有限公司 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途
WO2026092650A1 (zh) * 2024-11-01 2026-05-07 迈威(上海)生物科技股份有限公司 一种抑制LPA基因表达的RNAi制剂及其应用
WO2026133253A1 (en) 2024-12-20 2026-06-25 Novartis Ag Combinations of antisense agents, pharmaceutical compositions and methods of use
CN120485189B (zh) * 2025-07-16 2025-10-17 北京悦康科创医药科技股份有限公司 靶向调控LPA基因表达的siRNA及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120230938A1 (en) 2006-08-18 2012-09-13 Arrowhead Madison Inc. Polyconjugates for In Vivo Delivery of Polynucleotides
WO2014134483A2 (en) * 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US20150045573A1 (en) 2013-08-07 2015-02-12 Arrowhead Madison Inc. Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
DE602004027798D1 (de) 2003-03-12 2010-08-05 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
WO2011141703A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
RU2013117288A (ru) * 2010-12-17 2015-01-27 Эрроухэд Рисерч Корпорейшн СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
MX347298B (es) 2010-12-29 2017-04-21 Arrowhead Res Corp Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima.
CA2842039A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
RU2624028C2 (ru) * 2012-05-24 2017-06-30 Ионис Фармасьютикалз, Инк. Способы и композиции для модулирования экспрессии аполипопротеина (а)
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
US20160272970A1 (en) 2015-03-17 2016-09-22 Arrowhead Madison Inc. RNA Interference Agents
TWI761305B (zh) 2015-05-29 2022-04-21 美商愛羅海德製藥公司 抑制Ｈｉｆ２α基因表現之組合物及方法
LT3329002T (lt) * 2015-07-31 2021-01-11 Alnylam Pharmaceuticals, Inc. Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai
JOP20170057B1 (ar) 2016-03-07 2022-03-14 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة كمركبات علاجية

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120230938A1 (en) 2006-08-18 2012-09-13 Arrowhead Madison Inc. Polyconjugates for In Vivo Delivery of Polynucleotides
WO2014134483A2 (en) * 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US20150045573A1 (en) 2013-08-07 2015-02-12 Arrowhead Madison Inc. Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Cardiovascular Translational Research,제8권,44-53면(2015.01.)*

Also Published As

Publication number Publication date
AU2022283623B2 (en) 2025-07-10
JP2024009262A (ja) 2024-01-19
EP3356529A2 (en) 2018-08-08
DK3356529T3 (da) 2021-11-08
UY36926A (es) 2017-04-28
KR102728481B1 (ko) 2024-11-12
US9932586B2 (en) 2018-04-03
WO2017059223A9 (en) 2017-08-17
AU2016331084A1 (en) 2018-04-19
KR20260046241A (ko) 2026-04-06
CO2018003678A2 (es) 2018-11-30
NZ741086A (en) 2023-11-24
PL3356529T3 (pl) 2021-12-20
PT3356529T (pt) 2021-11-04
EP4029941A1 (en) 2022-07-20
TWI880645B (zh) 2025-04-11
IL290566A (en) 2022-04-01
PE20181139A1 (es) 2018-07-17
JOP20160211B1 (ar) 2021-08-17
SI3356529T1 (sl) 2022-01-31
JP7116212B2 (ja) 2022-08-09
AU2025242219A1 (en) 2025-10-23
US20200263179A1 (en) 2020-08-20
TWI784934B (zh) 2022-12-01
EA038478B1 (ru) 2021-09-03
MX2022013010A (es) 2022-11-09
KR20240162596A (ko) 2024-11-15
TW202449154A (zh) 2024-12-16
AU2016331084B2 (en) 2022-09-08
JP7442574B2 (ja) 2024-03-04
EP3356529A4 (en) 2019-09-04
CL2018000803A1 (es) 2018-08-31
BR112018006489A2 (pt) 2018-10-09
MA43347B1 (fr) 2021-11-30
WO2017059223A2 (en) 2017-04-06
JP2021087459A (ja) 2021-06-10
HRP20211410T1 (hr) 2021-12-24
IL258333A (en) 2018-05-31
IL300438B2 (en) 2026-07-01
MY195796A (en) 2023-02-21
TW202332769A (zh) 2023-08-16
WO2017059223A3 (en) 2017-05-11
CR20180231A (es) 2018-05-31
MX2018003833A (es) 2018-06-18
US20180195070A1 (en) 2018-07-12
SMT202100622T1 (it) 2022-01-10
HUE055942T2 (hu) 2022-01-28
HK1259063A1 (en) 2019-11-22
KR20180052703A (ko) 2018-05-18
CA3310628A1 (en) 2026-06-21
EA201890864A1 (ru) 2018-09-28
IL300438B1 (en) 2026-03-01
MA43347A (fr) 2018-08-08
JP2022113835A (ja) 2022-08-04
JP6991966B2 (ja) 2022-02-03
NZ780687A (en) 2025-06-27
US20250115907A1 (en) 2025-04-10
JP2018529732A (ja) 2018-10-11
CN108368506A (zh) 2018-08-03
TWI836693B (zh) 2024-03-21
ZA202106265B (en) 2023-08-30
TW202600825A (zh) 2026-01-01
EP3356529B1 (en) 2021-08-25
AU2022283623A1 (en) 2023-02-02
IL290566B1 (en) 2023-03-01
IL290566B2 (en) 2023-07-01
SG10202008530TA (en) 2020-10-29
UA121998C2 (uk) 2020-08-25
JOP20210043A1 (ar) 2021-03-08
PH12018500713A1 (en) 2018-10-15
CA3000397A1 (en) 2017-04-06
US10662427B2 (en) 2020-05-26
ES2896298T3 (es) 2022-02-24
IL258333B (en) 2022-03-01
TW201726918A (zh) 2017-08-01
IL300438A (en) 2023-04-01
US20170096665A1 (en) 2017-04-06
JP2026040461A (ja) 2026-03-09
RS62523B1 (sr) 2021-11-30
TN2018000094A1 (en) 2019-07-08
LT3356529T (lt) 2021-12-27
CY1125263T1 (el) 2023-03-24

Similar Documents

Publication Publication Date Title
JP7442574B2 (ja) Ｌｐａの遺伝子発現の阻害のための組成物及び方法
CN111107853B (zh) 用于抑制载脂蛋白C-III (APOC3)的表达的RNAi试剂和组合物
CN108064313B (zh) 用于抑制因子xii的基因表达的组合物和方法
JP2024086876A (ja) アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物
HK1259063B (en) Compositions and methods for inhibiting gene expression of lpa
EA048832B1 (ru) Композиции и способы для ингибирования генной экспрессии лпа
BR112018006489B1 (pt) Agente de interferência de rna (rnai) da lipoproteína a (lpa), seus usos e composição farmacêutica

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)